After oncology, the central government may next cap trade margins for anti-infectives – the top-selling category in the market of medicines.
An analysis by the country’s drug price watchdog, National Pharmaceuticals Pricing Authority (NPPA), shows trade margins of more than 100 per cent in these drugs, as they were in cancer medicines.
“Our next focus is on non-oncology drugs, especially the anti-infective category. Our preliminary analysis shows this category also has high TMR, over 100% and may need capping,” a senior official privy to the development told News18.